{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:44:21Z","timestamp":1791902661334,"version":"4.3.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:00:00Z","timestamp":1780099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:00:00Z","timestamp":1780099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s13555-026-01773-3","type":"journal-article","created":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T11:40:59Z","timestamp":1780141259000},"page":"3513-3528","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real-World Ritlecitinib Treatment of Severe Alopecia Areata in the United States: Patient Characteristics and Physician Satisfaction According to a Secondary Database Analysis"],"prefix":"10.1007","volume":"16","author":[{"given":"Samantha K.","family":"Kurosky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley S.","family":"Cha-Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Austin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arash","family":"Mostaghimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chesahna","family":"Kindred","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevieve","family":"Gauthier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mojgan","family":"Sadrarhami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Ungar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,30]]},"reference":[{"issue":"2","key":"1773_CR1","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.autrev.2014.10.014","volume":"14","author":"N Islam","year":"2015","unstructured":"Islam N, Leung PS, Huntley AC, Gershwin ME. The autoimmune basis of alopecia areata: a comprehensive review. Autoimmun Rev. 2015;14(2):81\u20139.","journal-title":"Autoimmun Rev"},{"key":"1773_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.11","volume":"3","author":"CH Pratt","year":"2017","unstructured":"Pratt CH, King LE Jr., Messenger AG, Christiano AM, Sundberg JP. Alopecia areata. Nat Rev Dis Primers. 2017;3:17011.","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"1773_CR3","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.jaad.2019.08.032","volume":"82","author":"HH Lee","year":"2020","unstructured":"Lee HH, Gwillim E, Patel KR, et\u00a0al. Epidemiology of alopecia areata, ophiasis, totalis, and universalis: a systematic review and meta-analysis. J Am Acad Dermatol. 2020;82(3):675\u201382.","journal-title":"J Am Acad Dermatol"},{"key":"1773_CR4","doi-asserted-by":"publisher","first-page":"259","DOI":"10.2147\/CCID.S245649","volume":"13","author":"M Benigno","year":"2020","unstructured":"Benigno M, Anastassopoulos KP, Mostaghimi A, et\u00a0al. A large cross-sectional survey study of the prevalence of alopecia areata in the United States. Clin Cosmet Investig Dermatol. 2020;13:259\u201366.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"11","key":"1773_CR5","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1111\/jdv.14959","volume":"32","author":"MA Richard","year":"2018","unstructured":"Richard MA, Corgibet F, Beylot-Barry M, et\u00a0al. Sex- and age-adjusted prevalence estimates of five chronic inflammatory skin diseases in France: results of the \u00abOBJECTIFS PEAU\u00bb study. J Eur Acad Dermatol Venereol. 2018;32(11):1967\u201371.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"1773_CR6","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1111\/bjd.20628","volume":"186","author":"M Harries","year":"2022","unstructured":"Harries M, Macbeth AE, Holmes S, et\u00a0al. The epidemiology of alopecia areata: a population-based cohort study in UK primary care. Br J Dermatol. 2022;186(2):257\u201365.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1773_CR7","doi-asserted-by":"publisher","first-page":"51","DOI":"10.4103\/ijt.ijt_99_17","volume":"10","author":"E Darwin","year":"2018","unstructured":"Darwin E, Hirt PA, Fertig R, Doliner B, Delcanto G, Jimenez JJ. Alopecia areata: review of epidemiology, clinical features, pathogenesis, and new treatment options. Int J Trichology. 2018;10(2):51\u201360.","journal-title":"Int J Trichology"},{"issue":"1","key":"1773_CR8","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jaad.2017.04.1142","volume":"78","author":"LC Strazzulla","year":"2018","unstructured":"Strazzulla LC, Wang EHC, Avila L, et\u00a0al. Alopecia areata: an appraisal of new treatment approaches and overview of current therapies. J Am Acad Dermatol. 2018;78(1):15\u201324.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1773_CR9","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.jaad.2021.08.043","volume":"86","author":"BA King","year":"2022","unstructured":"King BA, Mesinkovska NA, Craiglow B, et\u00a0al. Development of the alopecia areata scale for clinical use: results of an academic-industry collaborative effort. J Am Acad Dermatol. 2022;86(2):359\u201364.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1773_CR10","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s41687-020-00240-7","volume":"4","author":"NVJ Aldhouse","year":"2020","unstructured":"Aldhouse NVJ, Kitchen H, Knight S, et\u00a0al. \u201c\u2018You lose your hair, what\u2019s the big deal?\u2019 I was so embarrassed, I was so self-conscious, I was so depressed\u201d: a qualitative interview study to understand the psychosocial burden of alopecia areata. J Patient Rep Outcomes. 2020;4(1):76.","journal-title":"J Patient Rep Outcomes"},{"issue":"1","key":"1773_CR11","doi-asserted-by":"publisher","first-page":"S62","DOI":"10.1016\/j.jisp.2020.05.007","volume":"20","author":"N Mesinkovska","year":"2020","unstructured":"Mesinkovska N, King B, Mirmirani P, Ko J, Cassella J. Burden of illness in alopecia areata: a cross-sectional online survey study. J Investig Dermatol Symp Proc. 2020;20(1):S62\u20138.","journal-title":"J Investig Dermatol Symp Proc"},{"issue":"10","key":"1773_CR12","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1016\/j.jid.2022.02.019","volume":"142","author":"M Senna","year":"2022","unstructured":"Senna M, Ko J, Glashofer M, Edison-Heredia E, Zhu B, Shapiro J. Predictors of QOL in patients with alopecia areata. J Invest Dermatol. 2022;142(10):2646\u201350.","journal-title":"J Invest Dermatol"},{"issue":"1","key":"1773_CR13","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s13555-022-00864-1","volume":"13","author":"K Gandhi","year":"2023","unstructured":"Gandhi K, Shy ME, Ray M, Fridman M, Vaghela S, Mostaghimi A. The association of alopecia areata-related emotional symptoms with work productivity and daily activity among patients with alopecia areata. Dermatol Ther (Heidelb). 2023;13(1):285\u201398.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"3","key":"1773_CR14","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s13555-021-00512-0","volume":"11","author":"A Mostaghimi","year":"2021","unstructured":"Mostaghimi A, Napatalung L, Sikirica V, et\u00a0al. Patient perspectives of the social, emotional and functional impact of alopecia areata: a systematic literature review. Dermatol Ther (Heidelb) 2021;11(3):867\u201383.","journal-title":"Dermatol Ther"},{"key":"1773_CR15","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2022.6085","author":"S Lauron","year":"2023","unstructured":"Lauron S, Plasse C, Vaysset M, et\u00a0al. Prevalence and odds of depressive and anxiety disorders and symptoms in children and adults with alopecia areata: a systematic review and meta-analysis. JAMA Dermatol. 2023. https:\/\/doi.org\/10.1001\/jamadermatol.2022.6085.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"1773_CR16","first-page":"59","volume":"20","author":"DA Lintzeri","year":"2022","unstructured":"Lintzeri DA, Constantinou A, Hillmann K, Ghoreschi K, Vogt A, Blume-Peytavi U. Alopecia areata - current understanding and management. J Dtsch Dermatol Ges. 2022;20(1):59\u201390.","journal-title":"J Dtsch Dermatol Ges"},{"issue":"10387","key":"1773_CR17","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1016\/S0140-6736(23)00222-2","volume":"401","author":"B King","year":"2023","unstructured":"King B, Zhang X, Harcha WG, et\u00a0al. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b\u20133 trial. Lancet. 2023;401(10387):1518\u201329.","journal-title":"Lancet"},{"issue":"2","key":"1773_CR18","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1093\/bjd\/ljae385","volume":"192","author":"MJ Harries","year":"2025","unstructured":"Harries MJ, Ascott A, Asfour L, et\u00a0al. British Association of Dermatologists living guideline for managing people with alopecia areata 2024. Br J Dermatol. 2025;192(2):190\u2013205.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1773_CR19","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jaad.2020.03.004","volume":"83","author":"N Meah","year":"2020","unstructured":"Meah N, Wall D, York K, et\u00a0al. The Alopecia Areata Consensus of Experts (ACE) study: results of an international expert opinion on treatments for alopecia areata. J Am Acad Dermatol. 2020;83(1):123\u201330.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1773_CR20","doi-asserted-by":"publisher","first-page":"609","DOI":"10.23736\/S0392-0488.19.06458-7","volume":"154","author":"A Rossi","year":"2019","unstructured":"Rossi A, Muscianese M, Piraccini BM, et\u00a0al. Italian guidelines in diagnosis and treatment of alopecia areata. G Ital Dermatol Venereol. 2019;154(6):609\u201323.","journal-title":"G Ital Dermatol Venereol"},{"issue":"10","key":"1773_CR21","doi-asserted-by":"publisher","first-page":"e876","DOI":"10.1111\/1346-8138.17859","volume":"52","author":"M Ohyama","year":"2025","unstructured":"Ohyama M, Ito T, Amoh Y, et\u00a0al. Japanese Dermatological Association\u2019s Clinical Practice Guidelines for Alopecia Areata 2024: a complete English translated version. J Dermatol. 2025;52(10):e876\u2013907.","journal-title":"J Dermatol"},{"key":"1773_CR22","doi-asserted-by":"publisher","first-page":"371","DOI":"10.2147\/DMSO.S120101","volume":"9","author":"V Higgins","year":"2016","unstructured":"Higgins V, Piercy J, Roughley A, et\u00a0al. Trends in medication use in patients with type 2 diabetes mellitus: a long-term view of real-world treatment between 2000 and 2015. Diabetes Metab Syndr Obes Targets Ther. 2016;9:371\u201380.","journal-title":"Diabetes Metab Syndr Obes Targets Ther"},{"issue":"11","key":"1773_CR23","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1185\/03007990802457040","volume":"24","author":"P Anderson","year":"2008","unstructured":"Anderson P, Benford M, Harris N, Karavali M, Piercy J. Real-world physician and patient behaviour across countries: Disease-Specific Programmes\u2014a means to understand. Curr Med Res Opin. 2008;24(11):3063\u201372.","journal-title":"Curr Med Res Opin"},{"issue":"8","key":"1773_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-010352","volume":"6","author":"SM Babineaux","year":"2016","unstructured":"Babineaux SM, Curtis B, Holbrook T, Milligan G, Piercy J. Evidence for validity of a national physician and patient-reported, cross-sectional survey in China and UK: the Disease Specific Programme. BMJ Open. 2016;6(8):e010352.","journal-title":"BMJ Open"},{"key":"1773_CR25","unstructured":"Health Information Technology Act. Health Information Technology Act; 2009."},{"key":"1773_CR26","doi-asserted-by":"publisher","DOI":"10.1111\/pde.15378","author":"M Hordinsky","year":"2023","unstructured":"Hordinsky M, Hebert AA, Gooderham M, et\u00a0al. Efficacy and safety of ritlecitinib in adolescents with alopecia areata: results from the ALLEGRO phase 2b\/3 randomized, double-blind, placebo-controlled trial. Pediatr Dermatol. 2023. https:\/\/doi.org\/10.1111\/pde.15378.","journal-title":"Pediatr Dermatol"},{"issue":"2","key":"1773_CR27","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1093\/bjd\/ljae365","volume":"192","author":"M Piliang","year":"2025","unstructured":"Piliang M, Soung J, King B, et\u00a0al. Efficacy and safety of the oral Janus kinase 3\/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase IIb\/III and long-term phase III clinical studies in alopecia areata. Br J Dermatol. 2025;192(2):215\u201327.","journal-title":"Br J Dermatol"},{"key":"1773_CR28","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20526","author":"C Tziotzios","year":"2025","unstructured":"Tziotzios C, Sinclair R, Lesiak A, et\u00a0al. Long-term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: results from the ALLEGRO-LT phase 3, open-label study. J Eur Acad Dermatol Venereol. 2025. https:\/\/doi.org\/10.1111\/jdv.20526.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1773_CR29","doi-asserted-by":"publisher","DOI":"10.1177\/23743735251346633","author":"JM Mandelin","year":"2025","unstructured":"Mandelin JM, Rehn L, Kosunen M, V\u00e4kev\u00e4inen M, Rannanp\u00e4\u00e4 S. The diverse experiences and challenges of individuals with alopecia areata: survey results from Finland. J Patient Exp. 2025. https:\/\/doi.org\/10.1177\/23743735251346633.","journal-title":"J Patient Exp"},{"key":"1773_CR30","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-024-01280-3","author":"P Anderson","year":"2024","unstructured":"Anderson P, Piercy J, Austin J, et\u00a0al. Alopecia areata treatment patterns and satisfaction: results of a real-world cross-sectional survey in Europe. Dermatol Ther (Heidelb). 2024. https:\/\/doi.org\/10.1007\/s13555-024-01280-3.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"2","key":"1773_CR31","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s40257-024-00846-3","volume":"25","author":"B King","year":"2024","unstructured":"King B, Soung J, Tziotzios C, et\u00a0al. Integrated safety analysis of ritlecitinib, an oral JAK3\/TEC family kinase inhibitor, for the treatment of alopecia areata from the ALLEGRO clinical trial program. Am J Clin Dermatol. 2024;25(2):299\u2013314.","journal-title":"Am J Clin Dermatol"},{"key":"1773_CR32","doi-asserted-by":"crossref","unstructured":"Senna M, Hanna S, Ueki R, et\u00a0al. Updated integrated safety analysis of ritlecitinib up to ~5 years in patients with alopecia areata from the ALLEGRO clinical trial program. EADV Congress 2025. Paris, France; 2025.","DOI":"10.25251\/0j9fht97"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01773-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01773-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01773-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T03:23:49Z","timestamp":1781753029000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01773-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,30]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1773"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01773-3","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,30]]},"assertion":[{"value":"12 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Samantha K Kurosky, Ashley S Cha-Silva, Genevieve Gauthier, and Mojgan Sadrarhami are employees of Pfizer Inc and may own stock\/stock options in Pfizer Inc. Jenny Austin and Peter Anderson are employees of Adelphi Real World, Bollington, UK. Arash Mostaghimi reports personal fees from hims and hers, AbbVie, Sun Pharmaceuticals, Pfizer Inc, Digital Diagnostics, Lilly, ASLAN, Ingelheim, Figure 1 Co, and ACOM. Chesahna Kindred has been a speaker and\/or advisory board member for Aerolase, Eli Lilly and Company, Janssen, Pfizer Inc, Regeneron, Sanofi, Selphyl, Sun Pharma, and UCB Pharma; has been a consultant for AbbVie, Novartis, and Pfizer Inc; has been a steering committee member for Janssen; and has been a journal editor for\n                      Cutis\n                      . Benjamin Ungar is an employee of Mount Sinai and has received research funds (grants paid to the institution) from\u00a0Bristol Myers Squibb, Incyte, Rapt Therapeutics, Pfizer, and Sanofi. He is also a consultant for AbbVie, Arcutis Biotherapeutics, Bristol Myers Squibb, Botanix Pharmaceuticals, Castle Biosciences, Ebla Holdco, Fresenius Kabi, Galderma, J&J, Leo Pharma, Lilly, Pfizer, Primus Pharmaceuticals, Sanofi, Sun Pharma, UCB, Veradermics, and VRG Therapeutics.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"A complete description of the methods of the survey has been previously published and validated [\n                      \n                      \u2013\n                      \n                      ]. Permission was obtained from the owner of the Adelphi Real World AA II US DSP to use the database for this study. Using a check box, patients provided informed consent for use of their anonymized and aggregated data for research and publication in scientific journals. Data were collected in such a way that patients and physicians could not be identified directly; all data were aggregated and de-identified before receipt. Data collection was undertaken in line with European Pharmaceutical Marketing Research Association guidelines, and as such it does not require ethics committee approval. Each survey was performed in full accordance with relevant legislation at the time of data collection, including the Health Information Technology for Economic and Clinical Health Act legislation [\n                      \n                      ].","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}